Oxurion NV (GB:0G99) has released an update.
Oxurion NV has successfully terminated its private judicial reorganization procedure after reaching amicable agreements with its key creditors, reducing its debt from €14.7 million to €11.2 million. The company, which focuses on therapies for retinal diseases, is not actively negotiating further agreements but may do so in the future.
For further insights into GB:0G99 stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
